Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium

The hypoxic areas of solid cancers represent a negative prognostic factor irrespective of which treatment modality is chosen for the patient. Still, after almost 80 years of focus on the problems created by hypoxia in solid tumours, we still largely lack methods to deal efficiently with these treatment-resistant cells. The consequences of this lack may be serious for many patients: Not only is there a negative correlation between the hypoxic fraction in tumours and the outcome of radiotherapy as well as many types of chemotherapy, a correlation has been shown between the hypoxic fraction in tu... Mehr ...

Verfasser: Isabella Moser
Brad Wouters
Gerald Urban
Hilda Mujcic
Hubert Flamm
Yihai Cao
Jacques Pouysségur
Dan Cojocari
Kasper M.A. Rouschop
Heidi Lyng
Andrea Scozzafava
Silvia Pastorekova
Jan Alsner
Kjersti Flatmark
James Meehan
Agnes Görlach
Morten Busk
Afshan Ahmed
Ibtissam Marchiq
Ian Kunkler
Scott K. Parks
Nathalie M. Mazure
Kasper Toustrup
Manuel O. Landázuri
Marianne Koritzinsky
Peter Ebbesen
Johanna Chiche
Gerhard Jobst
Jens Overgaard
Andreas Weltin
Adrian L. Harris
Kaye J. Williams
Claudiu T. Supuran
Anne Hansen Ree
Philippe Lambin
Ludwig Dubois
Erik O. Pettersen
Luis del Peso
Dean C. Singleton
Francesca M. Buffa
Simon P. Langdon
Carol Ward
Maria J. Calzada
Jochen Kieninger
Syed Haider
Margaret Ashcroft
Roben G. Gieling
Dokumenttyp: Artikel
Erscheinungsdatum: 2014
Schlagwörter: Netherlands / Drug Discovery / Pharmacology / General Medicine
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27591172
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://www.openaccessrepository.it/record/120385

The hypoxic areas of solid cancers represent a negative prognostic factor irrespective of which treatment modality is chosen for the patient. Still, after almost 80 years of focus on the problems created by hypoxia in solid tumours, we still largely lack methods to deal efficiently with these treatment-resistant cells. The consequences of this lack may be serious for many patients: Not only is there a negative correlation between the hypoxic fraction in tumours and the outcome of radiotherapy as well as many types of chemotherapy, a correlation has been shown between the hypoxic fraction in tumours and cancer metastasis. Thus, on a fundamental basis the great variety of problems related to hypoxia in cancer treatment has to do with the broad range of functions oxygen (and lack of oxygen) have in cells and tissues. Therefore, activation-deactivation of oxygen-regulated cascades related to metabolism or external signalling are important areas for the identification of mechanisms as potential targets for hypoxia-specific treatment. Also the chemistry related to reactive oxygen radicals (ROS) and the biological handling of ROS are part of the problem complex. The problem is further complicated by the great variety in oxygen concentrations found in tissues. For tumour hypoxia to be used as a marker for individualisation of treatment there is a need for non-invasive methods to measure oxygen routinely in patient tumours. A large-scale collaborative EU-financed project 2009-2014 denoted METOXIA has studied all the mentioned aspects of hypoxia with the aim of selecting potential targets for new hypoxia-specific therapy and develop the first stage of tests for this therapy. A new non-invasive PET-imaging method based on the 2-nitroimidazole [(18)F]-HX4 was found to be promising in a clinical trial on NSCLC patients. New preclinical models for testing of the metastatic potential of cells were developed, both in vitro (2D as well as 3D models) and in mice (orthotopic grafting). Low density quantitative real-time polymerase ...